Tildacerfont - ≥98% , CAS No.1014983-00-6

CAS: 1014983-00-6 Cat. No.: T647313 Fórmula: C₂₀H₂₆ClN₅OS Peso molecular: 419.97

GRADE & PURITY ≥98%

Storage

Store at 2-8°C,Protected from light,Desiccated

Shipped In

Wet ice

Visão geral

Tildacerfont is a potent and orally active corticotrophin-releasing factor type 1 (CRF1) receptort antagonis. Tildacerfont effectively reduces adrenocorticotropic hormone (ACTH) and adrenal androgen levels. Tildacerfont has favourable safety profile. Tildacerfont can be used for researching congenital adrenal hyperplasia

Form:Solid

IC50& Target:CRF1 receptor

Specifications

Especificações e pureza

≥98%

Mecanismos bioquímicos e fisiológicos

Tildacerfont is a potent and orally active corticotrophin-releasing factor type 1 (CRF1) receptort antagonis. Tildacerfont effectively reduces adrenocorticotropic hormone (ACTH) and adrenal androgen levels. Tildacerfont has favourable safety profile. Tild

Condições de armazenamento de armazenamento

Store at 2-8°C,Protected from light,Desiccated

Enviado em

Wet ice

Este produto requer transporte de cadeia fria. Serviços terrestres e outros serviços econômicos não estão disponíveis.

Pureza

≥98%

Nomes e identificadores

• Sorrisos canónicos: CCC(CC)C1=CC(C)=NC2=C(C(C)=NN12)C3=C(N=C(S3)N4CCOCC4)Cl
• Peso molecular: 419.97

Application Protocols

No vendor-validated application protocols are provided for this item. The following general, non-item-specific guidance is offered for handling small-molecule tool compounds in biochemical or cell-based assays.

• Stock preparation: Dissolve compound in anhydrous DMSO to 10–50 mM. Vortex and sonicate if needed. Protect from light per storage guidance.
• Plate handling: Pre-dispense stocks into low-bind 96/384-well plates on ice or at 4–8 °C. Seal with solvent-resistant films. Limit headspace to reduce evaporation. Keep plates protected from light.
• Working concentrations: Establish an assay-specific range (e.g., 0.1 nM to 100 µM) using half-log serial dilutions. Maintain final DMSO ≤0.1–1% v/v depending on system tolerance.
• Controls: Include vehicle controls matching the highest DMSO level and positive/negative controls relevant to the assay readout.
• Adsorption/aggregation: Include a small amount of nonionic surfactant if compatible. Use low-bind plastics or glass vials; pre-rinse tips/plates with working buffer to reduce losses.
• Stability checks: Verify concentration and integrity by LC–MS/UPLC after thawing and after the assay period. Avoid multiple freeze–thaw cycles by aliquoting stocks on first use.

These steps are general best practices and should be adapted to your specific assay platform and institutional SOPs.

Biological Roles

Item-specific biological target, mechanism, or pathway information is not provided in this listing. No medical or clinical claims are made. For definitive target annotations, consult the primary literature and the item-specific CoA/Spec Sheet if available.

General guidance for deploying small-molecule research tools (not item-specific):

• Establish activity windows in your biological model using a concentration–response experiment (e.g., 10-point half-log dilution). Report potency metrics (EC50/IC50) with confidence intervals and Hill slopes.
• Confirm on-target engagement with at least one orthogonal assay (e.g., biochemical vs. cellular readouts), and include counter-screens to assess assay interference or nonspecific effects.
• Evaluate basic ADME-relevant properties that can influence in vitro results: solubility at assay pH, chemical stability (hydrolysis/oxidation), and nonspecific binding to plastic/serum proteins.
• Where photolability is a concern, follow the storage recommendation to protect from light; minimize exposure during assay setup.

If you require curated target/pathway metadata, please contact us for documentation or consult public chemical biology resources. The compound is supplied strictly for research use only.

Buffer Applications

This product is not a buffering agent. However, it is commonly necessary to formulate small-molecule tool compounds into biological buffers for assays. The following are general, non-item-specific practices:

• Vehicle strategy: Prepare a concentrated DMSO stock and dilute into the final buffer (e.g., PBS, HEPES, or assay-specific media) to a final DMSO content typically ≤0.1–1% v/v, depending on system tolerance.
• Precipitation control: Add the compound last into vigorously mixing buffer. Consider inclusion of 0.01–0.05% nonionic surfactant (e.g., Tween-20 or Pluronic F-127) to reduce aggregation and surface adsorption when compatible with the assay.
• pH considerations: If the compound is ionizable, maintain buffer pH within ±0.2 units of the desired value to minimize drift upon DMSO addition. Titrate pH after organic co-solvent addition when high precision is required.
• Adsorption mitigation: Use low-bind tubes/plates and pre-rinse with working buffer to reduce losses of hydrophobic analytes.
• Filtration: If sterility is required, filter the final working solution through a 0.22 µm low-protein-binding membrane. Verify no significant analyte loss to the filter.

These practices are general recommendations; confirm compatibility with your specific assay conditions.

Green Alternatives

As this product is a defined bioactive small molecule rather than a process solvent or reagent consumed in bulk, “green alternatives” are typically not applicable in the same sense as for solvents or catalysts.

Sustainability considerations for handling (general guidance):

• Choose greener dissolution vehicles where compatible with your assay (e.g., ethanol or aqueous cosolvent systems), recognizing that DMSO often remains necessary for hydrophobic analytes.
• Minimize solvent volumes by preparing higher-concentration stocks and using low-dead-volume pipetting.
• Implement plate-management practices that reduce waste (reusable plate seals where validated, consolidation of partial plates).
• Dispose of DMSO/organic waste via approved hazardous waste streams; segregate halogenated from non-halogenated waste to facilitate downstream treatment.

If your use case involves synthetic modification of the molecule (e.g., probe development), consider:

• Employing greener reaction media (2-MeTHF, CPME, water-enabled micellar catalysis) and catalytic vs. stoichiometric transformations where feasible (general literature guidance, not item-specific).

Because the compound itself is the object of study, not a consumable process aid, selection of an “alternative” compound alters the research objective and is generally not applicable.

Pharmaceutical Uses

This product is supplied strictly for research use only. No clinical, diagnostic, or therapeutic use is intended or permitted.

Formulation-related considerations for research contexts (general, not item-specific):

• Preformulation screening: Determine solubility across pH and cosolvents, susceptibility to hydrolysis/oxidation, and solid-state form (salt/polymorph) where known.
• Vehicle systems for in vivo research (non-clinical): Common vehicles include DMSO/PEG-400/saline or ethanol/PEG-400/saline mixtures; select based on solubility and tolerability of the model system. Verify concentration stability and absence of precipitation at use temperature.
• Excipient compatibility: Assess interactions with surfactants (e.g., polysorbates), cyclodextrins, or serum proteins that may alter free fraction in pharmacology studies.
• Analytical controls: Use qualified reference standards and stability-indicating LC methods to monitor dose solution integrity over the dosing window.

Regulatory note:

• No pharmacopeial monograph or GMP status is provided for this item. If your program requires GMP-grade or clinical-grade material, contact us for sourcing options or custom manufacture. Always adhere to institutional approvals for any non-clinical animal use.

Physical Properties

Only limited product-specific physical data are available in this listing.

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Melting point (literature/general): Not specified here; consult primary literature or CoA.
• Boiling point (literature/general): Not applicable/rarely used for characterization of solid bioactives; consult literature if needed.
• Density: Not specified for this item; refer to CoA/Spec Sheet.
• Solubility: Not specified for this item; refer to CoA/Spec Sheet. Practical guidance is provided under Solvent Selection.
• LogP/logD, pKa, refractive index, UV cutoff: Not specified for this item; refer to CoA/Spec Sheet.

General guidance for small-molecule bioactives (literature/practice, not item-specific):

• Many drug-like research compounds are sparingly soluble in water and are commonly handled as concentrated DMSO stocks (e.g., 10–50 mM) and diluted into assay buffer to achieve final organic content ≤1% v/v.
• If the compound contains ionizable groups, pH-adjusted aqueous cosolvent systems (DMSO or ethanol with buffer, plus ≤0.1% nonionic surfactant such as Tween-20) may improve apparent solubility and reduce adsorption to plastics.
• Verify actual solubility and polymorphism for this specific item via the CoA and in-house pre-formulation tests (shake-flask or kinetic solubility).

Quality and Grades

• Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet. If a numerical purity (e.g., HPLC area %) is critical for your application, request the lot-specific CoA prior to use.

What grade typically implies (general guidance):

• Research grade small molecules generally report purity by HPLC/UPLC (area normalization) alongside orthogonal identity confirmation (1H NMR and/or HRMS). Trace-level residual solvents are commonly evaluated by GC.
• Where applicable, salt form and polymorphic form are disclosed on the CoA; these can influence solubility and bioassay performance.

UV/LC readiness (general notes):

• HPLC-grade suitability implies low UV-absorbing impurities and a clean chromatographic profile; confirm via the CoA chromatogram for this lot.
• If you intend to use the compound as a quantitative analytical standard, verify assay purity, residual solvent content, and water content against your method validation criteria.

Stabilizers and additives:

• Stabilizer content: Not specified for this item; refer to CoA/Spec Sheet.

Documentation and traceability:

• Each shipment includes or provides access to an SDS. Lot-specific CoA with identity/purity data is available upon request. Contact us if you require additional documentation (QC methods, spectra, or impurity profiling).

Reaction and Applications

This product is supplied as a bioactive small molecule for research and screening. It is not typically employed as a synthetic reagent or catalyst.

Research uses (general, non-item-specific):

• Reference standard in biochemical and cellular assays for target/pathway interrogation.
• Tool compound in structure–activity relationship (SAR) panels and secondary pharmacology screening.
• Analytical spike/recovery control for method development (LC–MS/MS) in complex matrices.

If you intend to derivatize or immobilize the molecule for probe development, confirm the precise structure and functional handles (if any) from the item-specific CoA or primary literature. Absent those details, reaction planning cannot be reliably specified.

Tips for assay deployment (general best practice):

• Validate identity and purity upon receipt (UPLC/HRMS) when using as a reference standard.
• Establish compound solubility limits in your assay media by a quick turbidity or light-scattering screen across a dilution series.
• Include vehicle controls matched to the highest DMSO/organic percentage used.

For use in combinatorial or phenotypic screens, pre-plate DMSO stocks at desired concentrations under low-light conditions, seal to minimize evaporation, and store at 2–8 °C or −20 °C per your internal plate management SOPs.

Reaction Conditions

Not typically applicable. This product is intended as a bioactive small molecule for research and screening rather than as a synthetic reagent. No item-specific reaction conditions are provided.

If you plan to use the compound in chemical transformations (probe synthesis, conjugation), first obtain the exact structural information from the CoA or literature and then consult reaction conditions appropriate to the functional groups present. As general, non-item-specific reminders:

• Carry out small-scale feasibility tests to assess stability under proposed conditions (acid/base sensitivity, redox susceptibility, photolability).
• Prefer mild, chemoselective couplings (e.g., amide bond formation with modern coupling agents, click-type reactions) that limit degradation of complex aromatic scaffolds.
• Monitor reactions by LC–MS to avoid overexposure to harsh reagents or temperatures and to track potential isomerization/decomposition.

Because structural identifiers are not provided here, specific temperatures, catalysts, or yields cannot be offered.

Safety and Handling

Hazard information for this catalog item is not fully specified in the listing; consult the SDS for authoritative guidance.

• GHS classification: Not specified for this item; refer to SDS.
• Signal word, pictograms, H-statements: Not specified for this item; refer to SDS.

General laboratory precautions for small-molecule research solids (good practice, not item-specific):

• PPE: Wear lab coat, safety glasses, and suitable chemical-resistant gloves. Handle powders in a fume hood to minimize inhalation and exposure.
• Avoid generating dust and avoid skin/eye contact. Wash thoroughly after handling.
• Storage incompatibilities: Keep dry and protected from light. Store segregated from strong oxidizers and strong acids/bases unless compatibility is confirmed.
• Special risks: Drug-like aromatic compounds may be combustible organic solids; prevent ignition sources and manage fine particulates to avoid dust hazards.
• First aid (summary; defer to SDS): Inhalation—move to fresh air; Skin—wash with soap/water; Eyes—rinse with water for several minutes; Ingestion—rinse mouth. Seek medical attention if symptoms persist.
• Environmental handling: Prevent uncontrolled release to drains. Collect spills with inert absorbent and dispose of according to institutional chemical waste procedures.

Always review the item-specific SDS provided with your shipment for detailed hazard, toxicological, and disposal instructions.

Solvent Selection

For bioactive, aromatic small molecules such as Tildacerfont, DMSO-based handling is typically preferred. Item-specific solubility has not been provided in this listing; validate empirically.

Recommended approach (general best practices):

• Stock solutions: Prepare 10–50 mM stocks in anhydrous DMSO. Vortex and, if needed, gently warm (≤40 °C) and sonicate to aid dissolution. Filter (0.22 µm PTFE) if particulate remains.
• Aqueous working solutions: Dilute DMSO stocks into assay buffer with vigorous mixing to minimize precipitation. Keep final DMSO ≤0.1–1% v/v as allowed by your biological system.
• Alternative solvents: If DMSO is unsuitable, consider DMF, ethanol, or 1:1 ethanol:PEG-400 as intermediate vehicles. For in vitro buffers, small amounts of nonionic surfactant (e.g., 0.01–0.05% polysorbate) can enhance apparent solubility.
• Adsorption mitigation: For hydrophobic analytes, precondition plastic labware with buffer containing the same organic content, or use low-bind polypropylene or glass vials.
• Stability checks: Protect from light as specified. Assess stability by HPLC after repeated thaw–refreeze and over assay-relevant timeframes.

Quick comparison (general, not item-specific):

• DMSO: Highest solvating power, excellent for cryostable stocks, miscible with water; may affect certain enzyme/cell systems above ~0.5–1% v/v.
• Ethanol: Lower solvating power but widely tolerated biologically; evaporates readily—manage concentration drift.
• DMF: Strong solvent but more hygroscopic; use with care in biological contexts.

Storage and Reconstitution

Item-specific storage conditions are provided; follow strictly to preserve integrity.

• Storage temperature: Store at 2–8 °C.
• Light sensitivity: Protect from light.
• Moisture sensitivity: Store desiccated.
• Shipping: Shipped on wet ice.

Reconstitution guidance (general, not item-specific):

• Upon receipt, allow the container to equilibrate to room temperature in a desiccator before opening to prevent moisture condensation.
• Prepare concentrated stock solutions in anhydrous DMSO (typical 10–50 mM) under low-light conditions. Record exact concentration gravimetrically or by quantitative NMR if high accuracy is required.
• Aliquot stocks into low-bind, amber microtubes. Store tightly sealed to minimize solvent evaporation and water ingress.
• Freeze–thaw: Minimize cycles by aliquoting. If frozen storage of DMSO stocks is used, maintain consistent conditions (e.g., −20 °C) and verify absence of precipitation upon thaw. Do not store aqueous working solutions for extended periods unless stability has been established analytically.
• Stability monitoring: Check by HPLC/UPLC at defined intervals after storage. Discard solutions showing significant degradation, precipitation, or color change.

For any unspecified item-specific parameters (exact solubility, pH stability, salt form), consult the lot-specific CoA/Spec Sheet.

Structure and Identity

Tildacerfont is provided as a research-use small molecule in our screening library collection. Item-specific identifiers are limited in this listing.

• Product name: Tildacerfont (research chemical standard)
• CAS: 1014983-00-6 (literature identifier for the substance name)
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
• Synonyms/Code names: Not specified for this item; refer to CoA/Spec Sheet.

Structural description (general, literature-style, not item-specific):

• Tildacerfont is reported in the literature as a drug-like, heteroatom-containing, aromatic small molecule designed for target engagement in biological systems. Detailed ring systems, stereochemistry, and functional group annotations should be confirmed from the primary reference or the certificate of analysis (CoA) for this lot.

Notes

• This catalog entry is intended for qualified researchers who may already have a structure reference. If you require definitive structural descriptors (SMILES/InChI, exact formula), please request the item-specific CoA/Spec Sheet prior to purchase.

Synthetic Utility

Tildacerfont is supplied as a final small-molecule entity for biological research and screening; it is not typically used as a reagent, monomer, or catalyst in synthesis. Item-specific functional groups amenable to derivatization are not provided in this listing.

If chemical modification is desired (general guidance, not item-specific):

• Confirm the exact structure, functional handles, and salt/form via the item-specific CoA or primary literature before planning derivatization.
• Consider late-stage diversification strategies only if functional group tolerance and protecting-group strategy are clear from the structure (e.g., amide couplings, Suzuki cross-coupling on aryl halides, or nucleophilic substitutions on activated centers if present).
• For probe development, identify positions that tolerate substitution without abolishing activity through SAR mining of the literature, then design linkers for biotinylation or fluorophore conjugation with minimal perturbation of physicochemical properties.

Analytical support:

• Use orthogonal methods (UPLC-UV, HRMS, 1H/13C NMR) to confirm integrity after any transformation and to assess purity prior to biological testing.

Absent explicit structural details, specific synthetic routes or reaction conditions cannot be responsibly recommended for this item.

Target Specificity

No target, pathway, or binding specificity information is provided for this catalog item. Only item-specific data should appear here, and none are available in the Product Data.

• Target/antigen: Not specified for this item; refer to CoA/Spec Sheet.
• Species/reactivity: Not specified for this item; refer to CoA/Spec Sheet.
• Assay-validated activities: Not specified for this item; refer to CoA/Spec Sheet.

For biological characterization, consult primary literature databases or contact us for any documentation that may be available for your lot.